Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study.
Shao Z, Tong Z, Liu Q, Li W, Cai L, Shen K, Li H, Wang C, Yang J, Song Z, Wang S, Luo T, Zhao W, Wang H, Pan Y, Nie J, Zeng X, Bai Y, Chiang W, Guarnaccia V, Bi Y, Xu B.
Shao Z, et al.
Cancer Med. 2024 Aug;13(15):e7408. doi: 10.1002/cam4.7408.
Cancer Med. 2024.
PMID: 39136200
Free PMC article.
Clinical Trial.